Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer

Junker, Niels; Andersen, Mads Hald; Wenandy, Lynn; Dombernowsky, Sarah Louise; Kiss, Katalin; Sørensen, Christian Hjort; Therkildsen, Marianne Hamilton; Buchwald, Christian von; Andersen, Elo; Straten, Per thor; Svane, Inge Marie

doi:10.3109/14653249.2011.563291

Cited by 35 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number and localization of TIL within the tumor has been correlated with clinical outcome for different malignancies [87–89]. Isolation and ex vivo rapid expansion of TILs from melanoma and other malignancies is now readily achievable [85, 90, 91]. Infusion of large numbers of expanded autologous TIL (up to 10 11 ) to metastatic melanoma patients, followed by one course of high dose IL-2 as growth factor to sustain the persistence of TIL in vivo , resulted in 34% clinical response [92].…”

Section: Amplifying Existing Tumor Reactive T Cells: Adoptive T Cell mentioning

confidence: 99%

Advances in the development of cancer immunotherapies

Gao

Bernatchez

Sharma

et al. 2013

Trends in Immunology

View full text Add to dashboard Cite

Manipulating the immune system in order to induce clinically relevant responses against cancer is a longstanding goal. Interventions to enhance tumor specific immunity through vaccination, sustaining effector T cell activation, or increasing the numbers of tumor specific T cells using ex vivo expansion, have all resulted in clinical successes. Here we examine recent clinical advances and major ongoing studies in the field of cancer immunotherapy. Single agents have so far benefited a limited proportion of patients and future studies combining different types of immunotherapies and other therapeutic modalities, such as drugs against specific signaling pathways driving cancer cell growth, are needed to hopefully pave the way for the development of effective anti-cancer treatments causing durable responses.

show abstract

Section: Amplifying Existing Tumor Reactive T Cells: Adoptive T Cell mentioning

confidence: 99%

Advances in the development of cancer immunotherapies

Gao

Bernatchez

Sharma

et al. 2013

Trends in Immunology

View full text Add to dashboard Cite

show abstract

“…The TIL from largescale rapid expansions maintained both functional capacity and contained tumorspecifi c T cells. This study provides the basis for future clinical trials utilizing this method of ex vivo T cell expansion in adoptive cell transfers in HNSCC [ 272 ].…”

Section: Adoptive Cell Transfermentioning

confidence: 95%

“…A recent study evaluated a bimodal ex vivo expansion method to harvest tumorspecifi c T cells [ 272 ]. TIL bulk cultures were established from primary and recurrent HNSCC in high-dose IL-2.…”

Section: Adoptive Cell Transfermentioning

confidence: 99%

“…For example, p53-specifi c CTL can be expanded in patients with HNSCC [ 281 ]. By using autologous DC pulsed with the HLA-A2.1restricted wt p53 [264][265][266][267][268][269][270][271][272] CTL-specifi c clones could be expanded in vitro and detected in vivo from the PBMCs of many HNSCC patients. Interestingly, while p53-specifi c T cells could be expanded and detected in vivo from the group of patients whose tumors express low levels of p53, the group of patients whose tumor expresses high levels of p53 showed fewer circulating P53-specifi c CTLs that only rarely could be expanded in vitro [ 281 ].…”

Section: Antitumor Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Tumor Immunology and Immunotherapy

Rosenblatt¹,

Podack

Barber³

et al. 2014

View full text Add to dashboard Cite

“…TIL bulk cultures were established from HNSCC lesions by high-dose IL-2, then stimulated with anti-CD3 antibody and feeder tumor cells. The study showed that TILs could be expanded from 80% of patients in 17 days [55]. Since infection with high-risk human papilloma virus (HPV) is associated with HNSCC and viral proteins E6 and E7 are specifically expressed by tumor cells, they are ideal targets for T-cell adoptive transfer therapies.…”

Section: Categories Of Immunotherapymentioning

confidence: 99%

Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Schutt

Bumm

Mirandola

et al. 2012

International Reviews of Immunology

View full text Add to dashboard Cite

Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of local–regional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

show abstract

Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer

Cited by 35 publications

References 39 publications

Advances in the development of cancer immunotherapies

Advances in the development of cancer immunotherapies

Advances in Tumor Immunology and Immunotherapy

Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About